SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharma soars on reporting 32% jump in Q2 net profit

26 Oct 2017 Evaluate

Glaxosmithkline Pharmaceuticals is currently trading at Rs. 2495.25, up by 72.45 points or 2.99% from its previous closing of Rs. 2422.80 on the BSE.

The scrip opened at Rs. 2440.00 and has touched a high and low of Rs. 2538.00 and Rs. 2440.00 respectively. So far 3371 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2999.90 on 28-Oct-2016 and a 52 week low of Rs. 2309.05 on 30-May-2017.

Last one week high and low of the scrip stood at Rs. 2538.00 and Rs. 2381.10 respectively. The current market cap of the company is Rs. 21175.75 crore.

The promoters holding in the company stood at 75.00%, while institutions and non-institutions held 12.32% and 12.68% respectively.

Glaxosmithkline Pharmaceuticals has reported a rise of 31.84% in its net profit at Rs 130.32 crore for the quarter under review as compared to net profit of Rs 98.85 crore for the same quarter in the previous year. Total income of the company increased by 3.51% at Rs 845.87 crore for Q2FY18 as compared Rs 817.20 crore for the corresponding quarter previous year.

GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Glaxosmithkline Phar Share Price

2432.10 -19.70 (-0.80%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×